DAE HWA Pharmaceutical Co. Ltd (067080) — Cash Flow-to-Debt Ratio
DAE HWA Pharmaceutical Co. Ltd (067080) has a Cash Flow-to-Debt Ratio of 0.00x as of March 2026, meaning its operating cash flow of ₩314.63 Million could theoretically repay 0% of its total liabilities (₩137.27 Billion) in one year. Explore 067080 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
DAE HWA Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for DAE HWA Pharmaceutical Co. Ltd across 15 annual periods. Also explore DAE HWA Pharmaceutical Co. Ltd asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for DAE HWA Pharmaceutical Co. Ltd (2011–2025)
Year-by-year debt coverage analysis for DAE HWA Pharmaceutical Co. Ltd. For market capitalisation and broader financial context, see market value of DAE HWA Pharmaceutical Co. Ltd.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | ₩5.43 Billion | ₩131.72 Billion | ▼ -9.9% |
| 2024 | 0.05x | ₩6.13 Billion | ₩133.89 Billion | ▲ +1231.3% |
| 2023 | 0.00x | ₩-590.27 Million | ₩145.93 Billion | ▼ -106.1% |
| 2022 | 0.07x | ₩8.05 Billion | ₩121.06 Billion | ▼ -37.8% |
| 2021 | 0.11x | ₩10.45 Billion | ₩97.70 Billion | ▲ +243.1% |
| 2020 | 0.03x | ₩2.90 Billion | ₩93.07 Billion | ▲ +6686.3% |
| 2019 | 0.00x | ₩-41.07 Million | ₩86.80 Billion | ▼ -100.4% |
| 2018 | 0.12x | ₩10.49 Billion | ₩85.17 Billion | ▼ -0.2% |
| 2017 | 0.12x | ₩10.94 Billion | ₩88.72 Billion | ▲ +23.0% |
| 2016 | 0.10x | ₩8.79 Billion | ₩87.65 Billion | ▲ +162.2% |
| 2015 | 0.04x | ₩2.43 Billion | ₩63.55 Billion | ▼ -59.4% |
| 2014 | 0.09x | ₩6.18 Billion | ₩65.57 Billion | ▼ -58.4% |
| 2013 | 0.23x | ₩13.57 Billion | ₩59.84 Billion | ▲ +170.4% |
| 2012 | 0.08x | ₩5.77 Billion | ₩68.80 Billion | ▲ +92.2% |
| 2011 | 0.04x | ₩3.43 Billion | ₩78.60 Billion | — |